Vasilopoulou, E;
Winyard, PJ;
Riley, PR;
Long, DA;
(2015)
The role of thymosin-β4 in kidney disease.
[Editorial comment].
Expert Opinion on Biological Therapy
, 15
, Article Supplement 1. 10.1517/14712598.2015.1009891.
Preview |
Text
Vasilopoulou et al thymosin b4 kidney disease review revision for ucl discovery_template.pdf Download (183kB) | Preview |
Abstract
Therapies that modulate inflammation and fibrosis have the potential to reduce the morbidity and mortality associated with chronic kidney disease (CKD). A promising avenue may be manipulating thymosin-β4, a naturally occurring peptide, which is the major G-actin sequestering protein in mammalian cells and a regulator of inflammation and fibrosis. Thymosin-β4 is already being tested in clinical trials for heart disease and wound healing. This editorial outlines the evidence that thymosin-β4 may also have therapeutic benefit in CKD.
Type: | Article |
---|---|
Title: | The role of thymosin-β4 in kidney disease |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1517/14712598.2015.1009891 |
Publisher version: | http://dx.doi.org/10.1517/14712598.2015.1009891 |
Language: | English |
Additional information: | This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Biological Therapy on 22/06/15, available online: http://wwww.tandfonline.com/10.1517/14712598.2015.1009891 |
Keywords: | Ac-SDKP, fibrosis, inflammation, kidney disease, thymosin-β4 |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept |
URI: | https://discovery.ucl.ac.uk/id/eprint/1462790 |
Archive Staff Only
View Item |